Emicizumab for the treatment of haemophilia A: a narrative review

被引：45

作者：

Franchini, Massimo ^{[1
,2
]}

Marano, Giuseppe ^{[2
]}

Pati, Ilaria ^{[2
]}

Candura, Fabio ^{[2
]}

Profili, Samantha ^{[2
]}

Veropalumbo, Eva ^{[2
]}

Masiello, Francesca ^{[2
]}

Catalano, Liviana ^{[2
]}

Piccinini, Vanessa ^{[2
]}

Vaglio, Stefania ^{[2
]}

Pupella, Simonetta ^{[2
]}

Liumbruno, Giancarlo M. ^{[2
]}

机构：

[1] Carlo Poma Hosp, Dept Haematol & Transfus Med, Str Lago Paiolo 10, I-46100 Mantua, Italy

[2] Natl Inst Hlth, Italian Natl Blood Ctr, Rome, Italy

来源：

BLOOD TRANSFUSION | 2019年 / 17卷 / 03期

关键词：

emicizumab; haemophilia A; inhibitors; bleeding; BISPECIFIC ANTIBODY; FACTOR-VIII; PHARMACOLOGICAL THERAPIES; BLEEDING EPISODES; PROPHYLAXIS; ACE910; RECOMMENDATIONS; DIAGNOSIS; FUTURE; MODEL;

D O I：

10.2450/2019.0026-19

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

One of the most serious complications of the treatment of severe haemophilia A is the development of alloantibodies against exogenous factor VIII ( FVIII). Inhibitors render factor replacement therapy ineffective, exposing patients to a remarkably high risk of morbidity and mortality. Besides the well-known bypassing agents ( i.e. activated prothrombin complex concentrate and recombinant activated factor VII) used to treat or prevent bleeding in haemophilia patients with inhibitors, there is growing interest in newer haemostatic therapies that are not based on the replacement of the deficient FVIII. This review will focus on the most interesting among these innovative therapies, emicizumab, and will provide an update on its current stage of clinical development.

引用

页码：223 / 228

页数：6

共 46 条

[41] A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia [J].

Suster, Michael A. ;

Maji, Debnath ;

Nayak, Lalitha V. ;

Jenkins, Christina ;

Hunter, Susan ;

Schmaier, Alvin H. ;

Mohseni, Pedram ;

Ahuja, Sanjay .

BLOOD, 2018, 132

[42] Advances in the Treatment of Hemophilia: Implications for Laboratory Testing [J].

Tripodi, Armando ;

Chantarangkul, Veena ;

Novembrino, Cristina ;

Peyvandi, Flora .

CLINICAL CHEMISTRY, 2019, 65 (02) :254-262

[43]

U.S. Food and Drug Administration, 2018, FDA APPR EM KXWH HEM

[44] A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects [J].

Uchida, Naoki ;

Sambe, Takehiko ;

Yoneyama, Koichiro ;

Fukazawa, Naoki ;

Kawanishi, Takehiko ;

Kobayashi, Shinichi ;

Shima, Midori .

BLOOD, 2016, 127 (13) :1633-1641

[45] Emicizumab for hemophilia A with factor VIII inhibitors [J].

Young, Guy ;

Callaghan, Michael ;

Dunn, Amy ;

Kruse-Jarres, Rebecca ;

Pipe, Steven .

EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (11) :835-846

[46]

Young G, 2017, BLOOD, V130

← 1 2 3 4 5 →